Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
Open Access
- 1 January 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1) , ofad004
Abstract
Human papillomavirus (HPV) is an important cause of anogenital and oropharyngeal cancers, anogenital warts, and recurrent respiratory papillomatosis. Beginning in 2019, US guidelines recommended shared clinical decision-making (SCDM) for HPV vaccination among midadults (27–45 years). We conducted a narrative review of existing literature on HPV vaccination in midadults. The available evidence demonstrates that HPV vaccination in midadults is safe, efficacious, and likely to benefit both HPV-naïve midadults and those with previous infections. However, gaps in knowledge related to HPV vaccination have been identified among clinicians and midadult patients. Universal midadult HPV vaccination in the United States could avert 20 934–37 856 cancer cases over 100 years, costing $141 000–$1 471 000 per quality-adjusted life-year gained. Wide variation in these estimates reflects uncertainties in sexual behavior, HPV natural history, and naturally acquired immunity. Greater awareness among clinicians and midadult patients and broad implementation of SCDM may accelerate progress toward eliminating HPV-associated cancers and other diseases.Keywords
Funding Information
- Merck Sharp & Dohme
This publication has 65 references indexed in Scilit:
- HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological AssaysPLOS ONE, 2013
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UKSexually Transmitted Infections, 2011
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- Prevalence of and Risk Factors for Human Papillomavirus (HPV) Infection Among HIV-Seronegative Men Who Have Sex With MenThe Journal of Infectious Diseases, 2011
- Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 InfectionsJNCI: Journal of the National Cancer Institute, 2010
- The quality of life of patients with genital warts: a qualitative studyBMC Public Health, 2010
- Anal Cancer Screening: Barriers and Facilitators Among Ethnically Diverse Gay, Bisexual, Transgender, and Other Men Who Have Sex With MenJournal of Gay & Lesbian Social Services, 2008
- Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Vaccine, 2006
- Complexity, simplicity, and epidemiologyInternational Journal of Epidemiology, 2006